Human chorionic gonadotropin (HCG) injections are not approved by the U.S. Food and Drug Administration (FDA) for use during pregnancy. When administered to pregnant individuals—whether due to misdiagnosis, fertility protocol carryover, or off-label weight-loss regimens—the hormone poses documented physiological risks to both mother and fetus. Clinical data from the FDA Adverse Event Reporting System (FAERS) between 2015–2023 show 147 reported cases of ovarian hyperstimulation syndrome (OHSS), 32 instances of thromboembolic events, and 19 confirmed cases of fetal growth restriction linked to inadvertent HCG exposure after gestational week 5. This article presents peer-reviewed findings from sources including the American College of Obstetricians and Gynecologists (ACOG), the European Medicines Agency (EMA), and the Journal of Maternal-Fetal & Neonatal Medicine, with emphasis on measurable outcomes: serum estradiol spikes exceeding 4,000 pg/mL, mean gestational age at preterm delivery (34.2 ± 2.7 weeks), and placental weight reductions averaging 18.6% in exposed cohorts. No clinical benefit has been demonstrated for HCG administration beyond confirmed luteal phase support in early IVF cycles—never in established intrauterine pregnancy.
What Is HCG—and Why Is It Used Outside Pregnancy?
HCG is a glycoprotein hormone naturally produced by syncytiotrophoblast cells of the developing placenta. Its primary physiological role is to maintain the corpus luteum during early pregnancy, thereby sustaining progesterone production until placental luteal shift occurs around gestational week 8–10. Synthetic HCG is manufactured via recombinant DNA technology or urinary extraction and marketed under brand names including Ovidrel (recombinant, 250 mcg per prefilled syringe), Pregnyl (urinary-derived, available in 1,500 IU, 5,000 IU, and 10,000 IU vials), and Novarel (urinary-derived, 500 IU and 2,000 IU formulations). These products are FDA-indicated exclusively for ovulation induction in anovulatory women and for supporting early luteal phase in assisted reproductive technology (ART) cycles—not for use once pregnancy is confirmed.
The misconception that HCG injections improve pregnancy outcomes stems from outdated fertility protocols and unregulated weight-loss marketing. Between 2010–2018, over 2.1 million prescriptions for Ovidrel were dispensed in the U.S. alone, with approximately 12% of those administered after positive home pregnancy tests—per IMS Health pharmacy audit data. Such use contradicts ACOG Committee Opinion No. 743, which explicitly states: 'Exogenous HCG administration after pregnancy confirmation offers no proven benefit and introduces avoidable risk.'
Pharmacokinetics: How HCG Behaves in Pregnant Physiology
When injected intramuscularly or subcutaneously, HCG exhibits a half-life of 2.5–4.5 days in nonpregnant adults—but this extends significantly during pregnancy due to reduced renal clearance and increased binding to circulating alpha-2-macroglobulin. In pregnant women receiving 5,000 IU Pregnyl, serum HCG concentrations peak at 12–24 hours post-injection (mean: 18.3 hours), reaching levels of 1,250–3,800 mIU/mL—far exceeding endogenous pregnancy-associated HCG surges, which normally plateau at 50,000–100,000 mIU/mL by week 10. This exogenous surge triggers exaggerated luteinization, elevating estradiol and progesterone beyond physiologic thresholds. A 2021 cohort study published in American Journal of Obstetrics & Gynecology measured mean serum estradiol at 4,270 ± 890 pg/mL in women who received two 5,000 IU doses within 72 hours of confirmed pregnancy—compared to 1,840 ± 420 pg/mL in matched controls.
Documented Maternal Side Effects
Maternal complications associated with HCG injection during pregnancy fall into three major categories: endocrine disruption, vascular stress, and structural ovarian pathology. Unlike transient nausea or fatigue seen in normal early pregnancy, HCG-induced effects are dose-dependent, measurable, and often require intervention.
Ovarian Hyperstimulation Syndrome (OHSS)
OHSS is the most frequently reported adverse event. In pregnant patients, OHSS presents with rapid-onset ascites, hemoconcentration (hematocrit >45%), and ovarian enlargement (>12 cm bilaterally on ultrasound). FAERS data indicate 89% of OHSS cases linked to HCG exposure occurred within 4–10 days post-injection, with median symptom onset at day 6. Severity distribution among 147 reported cases: mild (42%), moderate (37%), severe (21%). Severe OHSS correlated strongly with baseline antral follicle count ≥20 and pre-injection AMH >4.5 ng/mL—both markers of high ovarian reserve. Treatment included paracentesis in 17 cases, ICU admission for respiratory compromise in 9, and 3 instances requiring therapeutic laparoscopy for torsion.
Notably, OHSS risk escalates with concurrent gonadotropin therapy. A 2022 retrospective review across 12 fertility clinics found that women receiving both FSH (Gonal-F, 150 IU daily) and HCG (Ovidrel) after conception had a 6.8-fold higher OHSS incidence versus those receiving HCG alone.
Thromboembolic Events and Cardiovascular Strain
HCG stimulates thrombopoietin receptors and upregulates PAI-1 (plasminogen activator inhibitor-1), increasing clotting potential. Among 32 thromboembolic events in FAERS, 19 were deep vein thromboses (DVTs), 8 were pulmonary emboli (PEs), and 5 involved cerebral venous sinus thrombosis. Median age was 32 years; 78% occurred between gestational weeks 6–14. D-dimer levels averaged 2,450 ng/mL FEU (normal <500), and 62% had concurrent protein S deficiency confirmed by functional assay. One fatal PE occurred in a 29-year-old woman at 9 weeks’ gestation following 10,000 IU Pregnyl—her antithrombin III level was 62% (normal 80–120%).
- Mean systolic blood pressure increase: +14.3 mmHg (range: +7 to +29)
- Median heart rate elevation: +12 bpm sustained over 48 hours
- Incidence of new-onset gestational hypertension: 11.4% in exposed cohort vs. 1.2% in unexposed (adjusted OR 10.2, 95% CI 5.7–18.3)
Fetal and Placental Impacts
While HCG does not cross the placental barrier in significant quantities, its systemic maternal effects directly impair uteroplacental perfusion and trophoblast function. The hormone’s binding to LH/hCG receptors on decidual and spiral artery smooth muscle induces vasoconstriction—reducing diastolic flow velocity in uterine arteries by up to 37%, per Doppler studies conducted at Columbia University Irving Medical Center.
Growth Restriction and Preterm Birth
In a prospective cohort of 83 pregnancies with documented HCG exposure (≥2,000 IU after ultrasound-confirmed intrauterine gestation), researchers tracked neonatal outcomes through 1 year. Mean birth weight was 2,410 g (SD ± 480 g), compared to 3,320 g (SD ± 410 g) in matched controls—a statistically significant 27% reduction in small-for-gestational-age (SGA) incidence (29.4% vs. 7.1%; p < 0.001). Preterm birth (<37 weeks) occurred in 38.6% of exposed infants versus 8.2% in controls. Median gestational age at delivery was 34.2 weeks (IQR 32.1–35.9).
Placental pathology revealed consistent abnormalities: reduced villous branching (mean terminal villi count/mm²: 12.4 vs. 21.7), increased fibrin deposition (score ≥3 on Amsterdam classification in 61% vs. 9%), and decreased placental weight (mean 428 g vs. 524 g; p = 0.002). These findings align with mechanistic studies showing HCG-induced downregulation of VEGF-A expression in cytotrophoblasts—critical for placental angiogenesis.
| Outcome Measure | HCG-Exposed Cohort (n=83) | Matched Controls (n=166) | p-value |
|---|---|---|---|
| Mean Birth Weight (g) | 2,410 ± 480 | 3,320 ± 410 | <0.001 |
| SGA Incidence (%) | 29.4% | 7.1% | <0.001 |
| Preterm Birth Rate (%) | 38.6% | 8.2% | <0.001 |
| Placental Weight (g) | 428 ± 92 | 524 ± 87 | 0.002 |
| Uterine Artery PI (median) | 1.87 | 1.02 | <0.001 |
Diagnostic Confusion and Laboratory Interference
HCG injections confound standard prenatal monitoring. Exogenous HCG persists in serum for up to 14 days post-injection, complicating interpretation of quantitative beta-HCG trends used to assess viability. For example, a woman receiving 5,000 IU Pregnyl on day 28 post-LMP will show serum beta-HCG values artificially inflated by 1,500–2,200 mIU/mL for at least one week—potentially masking a failing pregnancy or suggesting false reassurance.
More critically, HCG cross-reacts with luteinizing hormone (LH) assays. Commercial immunoassays—including Roche Elecsys, Siemens Immulite, and Abbott Architect platforms—exhibit 0.8–3.2% cross-reactivity with HCG at supraphysiologic concentrations. This leads to falsely elevated LH readings, misdiagnosing conditions like polycystic ovary syndrome (PCOS) or delaying recognition of pituitary dysfunction. In one documented case at Massachusetts General Hospital, a patient’s repeated LH values >25 IU/L (reference <7 IU/L) prompted unnecessary MRI for suspected pituitary adenoma—later resolved when exogenous HCG use was disclosed.
Impact on First-Trimester Screening
First-trimester combined screening (PAPP-A + free beta-HCG + NT ultrasound) relies on precise biomarker quantification. HCG injections skew free beta-HCG multiples of median (MoM) values by +1.8 to +3.4 MoM, invalidating risk calculations for trisomy 21. A 2020 quality assurance audit of 14 regional labs found that 12% of abnormal screen results in women with known recent HCG use were incorrectly classified as high-risk—leading to 37 unnecessary invasive procedures (CVS/amniocentesis) over 18 months.
Management and Clinical Recommendations
No antidote exists for exogenous HCG. Management is supportive and surveillance-based, guided by severity metrics and gestational timing.
- Immediate discontinuation of all HCG dosing upon pregnancy confirmation (via transvaginal ultrasound + serum beta-HCG)
- Serial monitoring: daily weights, abdominal girth, urine output, and twice-weekly ultrasounds for ovarian size/ascites if OHSS suspected
- Anticoagulation: prophylactic enoxaparin (40 mg SC daily) for women with prior VTE, thrombophilia, or D-dimer >1,500 ng/mL
- Fetal surveillance: Doppler assessment of uterine and umbilical arteries starting at 16 weeks; growth scans every 3 weeks from 24 weeks
- Delivery planning: Consider elective delivery at 37 weeks if persistent SGA pattern or abnormal Dopplers emerge
Providers must document explicit counseling using standardized language: 'HCG injections provide no benefit to your pregnancy and may harm you or your baby. Continuing them increases your risk of blood clots, premature birth, and poor fetal growth.' Documentation templates are available through the Society for Assisted Reproductive Technology (SART) and should be signed by patient and provider.
Regulatory Status and Legal Implications
The FDA has issued three safety communications regarding off-label HCG use since 2012, emphasizing that Ovidrel, Pregnyl, and Novarel carry boxed warnings against use in pregnant patients. Despite this, compounding pharmacies continue dispensing HCG for 'metabolic support'—a term absent from FDA labeling and unsupported by clinical trials. In 2023, the Federal Trade Commission (FTC) fined three direct-to-consumer telehealth platforms $4.2 million for marketing HCG injections to pregnant women as 'natural pregnancy enhancers.'
Medicolegally, failure to discontinue HCG after pregnancy confirmation may constitute deviation from standard of care. In a 2021 malpractice case (Smith v. Riverside OB-GYN Associates), a plaintiff delivered a 1,980 g infant at 33 weeks with grade III intraventricular hemorrhage; expert testimony established that continuation of Ovidrel after positive pregnancy test breached ACOG guidelines and contributed to placental insufficiency. The jury awarded $2.8 million in damages.
Prescribers are advised to verify pregnancy status via quantitative beta-HCG and pelvic ultrasound before each HCG dose in fertility patients—even if prior tests were negative. Protocols must include mandatory electronic health record (EHR) alerts triggered by any beta-HCG >5 mIU/mL. Major EHR vendors (Epic, Cerner) now embed these safeguards following Joint Commission Sentinel Event Alert #67.
Evidence-Based Alternatives and Support Strategies
Clinicians encountering patients requesting HCG during pregnancy should redirect toward interventions with robust safety and efficacy data:
- Progesterone supplementation: Micronized vaginal progesterone (Crinone 8% gel, 90 mg daily) is FDA-approved for luteal phase support and shows no association with OHSS or fetal harm in randomized trials (PROGESTA study, n=1,215)
- Nutritional optimization: Evidence-based prenatal vitamins containing 800 mcg folic acid (Nature Made Prenatal Multi + DHA), 27 mg iron (FerroSequels), and 600 IU vitamin D (Carlson Super Daily D3)
- Psychosocial support: Cognitive behavioral therapy (CBT) modules targeting health anxiety—validated in the PREGNANT trial (JAMA Internal Medicine, 2022)—reduced inappropriate supplement requests by 73% over 8 weeks
For patients engaged in unregulated weight-loss protocols involving HCG, referral to certified obesity medicine specialists (ABOM board-certified) is essential. The American Board of Obesity Medicine reports that 91% of patients discontinue HCG use within 4 weeks when provided with structured alternatives including GLP-1 receptor agonist education (semaglutide, liraglutide) and behavioral nutrition coaching.
Early childhood educators and pediatric providers play a critical role in identifying downstream developmental impacts. Children exposed to HCG in utero demonstrate higher rates of motor delay (18.3% vs. 4.1% at 24 months per Bayley-III scores) and require earlier Early Intervention referrals (mean age 11.2 months vs. 15.7 months). Collaborative care models integrating OB-GYN, maternal-fetal medicine, and developmental pediatrics yield best outcomes—particularly when initiated before 20 weeks’ gestation.
Public health messaging must emphasize clarity: HCG is a fertility drug—not a pregnancy supplement. Its administration after conception is neither routine nor benign. With over 400,000 pregnancies conceived annually via ART in the U.S., ensuring timely discontinuation remains a high-priority quality metric. As of Q2 2024, only 63% of SART-accredited clinics report automated EHR checks for pregnancy status prior to HCG dosing—a gap requiring urgent systems-level attention.
Patients deserve transparency rooted in data—not anecdotes. When clinicians cite measurable risks—like the 27% reduction in birth weight or 38.6% preterm birth rate—they empower informed decisions. This isn’t theoretical risk; it’s documented physiology, captured in lab values, ultrasound metrics, and neonatal outcomes. Prioritizing evidence over tradition protects both maternal autonomy and fetal well-being.
Resources for providers include the ACOG Practice Bulletin No. 233 (2022), the EMA Assessment Report on Chorionic Gonadotropins (EMA/CHMP/122944/2021), and the CDC’s Safe Motherhood Initiative Clinical Toolkit, all freely accessible online. Patient-facing materials are available in 12 languages via the March of Dimes website under 'Medication Safety in Pregnancy.'
Finally, accurate documentation matters. Every HCG prescription should include written indication, dose, route, and explicit pregnancy test result with date/time. In electronic prescribing systems, this information must populate structured fields—not free-text notes—to enable real-time safety analytics and audit readiness.
Responsible care means recognizing that some interventions, however well-intentioned, carry disproportionate risk. HCG injections during pregnancy fall squarely into that category—and the data leave no room for ambiguity.
